Algernon Pharmaceuticals’ patent application for NP-251 (Repirinast) has been accepted by the Japanese Patent Office (JPO) for the treatment of chronic kidney disease (CKD).

The company has announced that the JPO has issued a Notice of Allowance for the patent application.

The invention is for use in the prophylaxis or therapeutic treatment of renal fibrosis or kidney disease. It proposes using Repirinast either alone or along with telmisartan, a medicine used for the treatment of heart failure, high blood pressure, and diabetic kidney disease.

Originally developed by Mitsubishi Tanabe Pharma, Repirinast works by binding to receptors on mast cells and helps in preventing their degranulation. Algernon stated that this action could prevent fibrosis in multiple organs.

The treatment was previously sold and marketed under the brand name Romet in Japan to treat asthma.

Findings from a unilateral ureteral obstruction mouse model of kidney fibrosis showed that Repirinast reduced fibrosis by 51% with statistical significance.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The therapy also demonstrated significant improvement in combination with telmisartan.

Algernon Pharmaceuticals CEO Christopher Moreau said: “This is the first allowance notice received from the JPO by Algernon for one of the drugs being investigated under our innovative drug repurposing programme and is further validation of our intellectual property strategy.

“What is also noteworthy, is that Repirinast was originally developed and approved in the Japanese market for the treatment of asthma and so this notice of allowance is even more meaningful.”

The company has also filed the corresponding patent applications for the therapy in China, Canada, the US, and Europe.